Xometry launches auto-quotes for injection molding in US market

Published 23/10/2025, 14:14
Xometry launches auto-quotes for injection molding in US market

NORTH BETHESDA, Md. - Xometry, Inc. (NASDAQ:XMTR), a $2.47 billion market cap company with impressive revenue growth of 20.19% over the last twelve months, has expanded its AI-powered marketplace capabilities by introducing auto-quotes for injection molding services in the United States, the company announced Thursday in a press release. According to InvestingPro analysis, the stock appears to be trading above its Fair Value, despite maintaining a healthy gross profit margin of 39.15%.

The new feature follows what the company described as a successful earlier launch in European markets. The auto-quoting system reduces the quoting process from days to minutes, allowing customers to move more quickly from design to finished parts. This operational efficiency has contributed to the company’s remarkable 97.56% stock price gain over the past six months.

"By removing friction and reducing wait times, we’re helping engineers and procurement teams make faster, smarter decisions," said Vaidy Raghavan, Xometry’s Chief Technology Officer.

The service enables businesses to manage their injection molding needs through Xometry’s AI-powered platform, from initial quoting to delivery and reordering. Customers can select from various options including prototype tooling, low-volume bridge tooling, and high-volume production tooling.

According to the company, the platform supports a range of part sizes in over 35 different materials, colors, and finishes. The service is designed to accommodate both prototyping needs and full-scale production requirements.

Xometry operates an AI-powered marketplace connecting buyers and suppliers of custom manufacturing services. The company also owns the Thomasnet industrial sourcing platform, which together with its other services aims to digitize manufacturing procurement processes. For deeper insights into Xometry’s growth trajectory and financial health, including 13 additional ProTips and comprehensive valuation metrics, visit InvestingPro to access the detailed Pro Research Report.

In other recent news, Xometry, Inc. reported strong second-quarter financial results, with revenue, gross margin, and EBITDA surpassing analyst expectations. UBS responded to these results by raising its price target for Xometry from $35 to $40, while maintaining a Neutral rating. Citizens JMP also increased its price target to $50 from $45, citing the company’s better-than-expected financial performance, with revenue and EBITDA exceeding guidance by $5.5 million and $1.9 million, respectively. Additionally, Goldman Sachs downgraded Xometry from Buy to Neutral, despite raising the price target to $49, due to the stock’s recent strong performance.

Moreover, Xometry launched a new Workcenter Mobile App for its manufacturing partners, enhancing the management of job offers and production workflows. Citizens JMP reiterated its Market Outperform rating, maintaining a $50 price target based on positive trends in AI adoption, highlighted by Xometry’s Manufacturing Outlook survey. The survey found that 82% of manufacturing executives view artificial intelligence as a crucial growth driver. These developments reflect ongoing strategic moves and market reactions within Xometry’s operational landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.